Breaking News, Collaborations & Alliances

Ambrx, BeiGene Ink Next-Gen Biologics Pact

Ambrx to apply its proprietary Expanded Genetic Code platforms to discover novel biologic drug candidates

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ambrx, a clinical-stage biopharmaceutical company focused on the development of innovative protein therapeutics and BeiGene, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, have entered a global research and development collaboration.   Ambrx has developed proprietary Expanded Genetic Code technology platforms designed to allow the efficient incorporation of non-natural a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters